Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2021
|
Jacqualyn A Fouse Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,398
-5.5%
|
-
|
|
Feb 14
2021
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,333
+15.5%
|
-
|
|
Feb 14
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+24.42%
|
-
|
|
Feb 14
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,666
+37.34%
|
-
|
|
Feb 04
2021
|
John Maraganore Director |
SELL
Bona fide gift
|
Direct |
3,415
-11.32%
|
-
|
|
Jan 06
2021
|
Bruce Car Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,191
-14.38%
|
$52,404
$44.09 P/Share
|
|
Jan 06
2021
|
Bruce Car Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,437
+29.32%
|
-
|
|
Dec 03
2020
|
Jonathan Biller Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,707
-14.53%
|
$76,815
$45.87 P/Share
|
|
Dec 03
2020
|
Jonathan Biller Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,753
+32.87%
|
-
|